Advaxis Inc. (ADXS)

1.64
NASDAQ : Health Technology
Prev Close 1.69
Day Low/High 1.64 / 1.71
52 Wk Low/High 1.51 / 9.55
Avg Volume 1.05M
Exchange NASDAQ
Shares Outstanding 52.31M
Market Cap 88.41M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Advaxis To Present At Upcoming March Conferences

Advaxis To Present At Upcoming March Conferences

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, announced today that Company...

Short Interest In Advaxis Drops 36.7%

Short Interest In Advaxis Drops 36.7%

The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 3,020,486 share decrease in total short interest for Advaxis Inc , to 5,217,154, a decrease of 36.67% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Advaxis Reports Fiscal 2018 First Quarter Financial Results And Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca's IMFINZI® (Durvalumab)

Advaxis Reports Fiscal 2018 First Quarter Financial Results And Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca's IMFINZI® (Durvalumab)

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces financial results for the three months ended...

Advaxis To Host Business Update And First Quarter 2018 Financial Results Conference Call On March 12, 2018

Advaxis To Host Business Update And First Quarter 2018 Financial Results Conference Call On March 12, 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLMN, CENX, MMYT, ULH, USM Downgrades: CVV, DGICA, DGICB, INT, MELI, RMAX, VLP Initiations: ADXS Read on to get TheStreet Quant Ratings' detailed report:

Advaxis Prices $20.0 Million Public Offering Of Common Stock

Advaxis Prices $20.0 Million Public Offering Of Common Stock

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, announced today the pricing of...

Advaxis Announces Proposed Public Offering Of Common Stock

Advaxis Announces Proposed Public Offering Of Common Stock

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company ("Advaxis" or the "Company") focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends...

Advaxis Submits Conditional Marketing Authorization Application For Axalimogene Filolisbac For The Second-Line Treatment Of Metastatic Cervical Cancer In European Union

Advaxis Submits Conditional Marketing Authorization Application For Axalimogene Filolisbac For The Second-Line Treatment Of Metastatic Cervical Cancer In European Union

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization...

Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer

Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that data from an earlier Phase 2 clinical study of...

Short Interest Expands By 10% For ADXS

Short Interest Expands By 10% For ADXS

The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 751,352 share increase in total short interest for Advaxis Inc , to 8,236,371, an increase of 10.04% since 12/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Data Highlighting Advaxis' Antigen Delivery Platform Accepted For Multiple Presentations At 2018 Keystone Symposia Conference On Cancer Immunotherapies

Data Highlighting Advaxis' Antigen Delivery Platform Accepted For Multiple Presentations At 2018 Keystone Symposia Conference On Cancer Immunotherapies

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the Company's...

Advaxis' Immunotherapy In Combination With Chemoradiation Highlighted As Potential Treatment For Anal Cancer In International Journal Of Radiation Oncology

Advaxis' Immunotherapy In Combination With Chemoradiation Highlighted As Potential Treatment For Anal Cancer In International Journal Of Radiation Oncology

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated...

The January Effect Is on Time This Year

The January Effect Is on Time This Year

I continue to believe that biotech and biopharma stocks will outperform in 2018.

Advaxis Reports Fiscal Year 2017 Financial Results And Provides A Business Update

Advaxis Reports Fiscal Year 2017 Financial Results And Provides A Business Update

Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today provides a business update and announces its...

Advaxis To Host Business Update And Fiscal Year End 2017 Financial Results Conference Call On December 21, 2017

Advaxis To Host Business Update And Fiscal Year End 2017 Financial Results Conference Call On December 21, 2017

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will release financial results for...

Advaxis To Present At The Jefferies 2017 London Healthcare Conference

Advaxis To Present At The Jefferies 2017 London Healthcare Conference

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that company management will participate in...

Advaxis To Receive $4.5 Million Through The New Jersey Economic Development Authority NOL Program

Advaxis To Receive $4.5 Million Through The New Jersey Economic Development Authority NOL Program

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, has received approval for a $4.

Short Interest Decreases By 15.8% For ADXS

Short Interest Decreases By 15.8% For ADXS

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,568,524 share decrease in total short interest for Advaxis Inc , to 8,368,164, a decrease of 15.79% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Small Caps Continue to Outperform on Tax Reform, Oil Marches Higher - ICYMI

Small Caps Continue to Outperform on Tax Reform, Oil Marches Higher - ICYMI

Here's what you need to know now for Wednesday, Sept. 27.

Advaxis To Webcast Company Overview At The Cantor Fitzgerald Global Healthcare Conference

Advaxis To Webcast Company Overview At The Cantor Fitzgerald Global Healthcare Conference

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced its company overview at the Cantor Fitzgerald Global...

Interesting ADXS Call Options For November 17th

Interesting ADXS Call Options For November 17th

Investors in Advaxis Inc saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADXS options chain for the new November 17th contracts and identified the following call contract of particular interest.

Two Abstracts Featuring Advaxis' Lm-based Candidates Selected For Presentation At The 32nd Annual Society For Immunotherapy Cancer (SITC) Meeting

Two Abstracts Featuring Advaxis' Lm-based Candidates Selected For Presentation At The 32nd Annual Society For Immunotherapy Cancer (SITC) Meeting

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced two abstracts were selected for presentation at...

Advaxis To Present At Cantor Fitzgerald Global Healthcare Conference

Advaxis To Present At Cantor Fitzgerald Global Healthcare Conference

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Anthony Lombardo, interim chief executive officer,...

Relative Strength Alert For Advaxis

Relative Strength Alert For Advaxis

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Advaxis Reports Business Update And Third Quarter 2017 Results

Advaxis Reports Business Update And Third Quarter 2017 Results

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today provided a business update and announced its financial...

Advaxis To Present At Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival

Advaxis To Present At Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced three abstracts were selected for presentation at...

Advaxis Lead Immunotherapy Candidate Continues To Build Recognition Among Industry Leaders

Advaxis Lead Immunotherapy Candidate Continues To Build Recognition Among Industry Leaders

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products based on its proprietary Lm-based antigen delivery system, today...

TheStreet Quant Rating: E+ (Sell)